Molecular diagnostics still drives more than half of clinical diagnostics revenue, with PCR and NAAT accounting for 52% of molecular diagnostic market income. At the same time, 48% of labs deliver stat chemistry panels with a median turnaround time under 24 hours, yet pre-analytical issues continue to reject 2.6% of specimens and contribute to 1 in 6 laboratory errors. U.S. Medicare spending on laboratory services reached $15.1 billion in 2023, putting labor and process controls under tighter cost pressure.
Key Takeaways
- In the U.S., clinical laboratory technicians had a mean annual wage of $53,560 in 2023 (BLS, Occupational Employment and Wage Statistics).
- In the U.S., clinical laboratory technologists had a mean annual wage of $71,440 in 2023 (BLS, Occupational Employment and Wage Statistics).
- U.S. Medicare spending on “Laboratory services” increased to $15.1 billion in 2023 (CMS, Medicare claims data dashboard).
- The global IVD market is projected to grow at a CAGR of 5.7% from 2022 to 2028 (GlobalData, IVD market forecast).
- The U.S. IVD market is projected to reach $35.0 billion by 2030 (Fortune Business Insights market forecast).
- India’s in-vitro diagnostics (IVD) market size is projected to reach $16.2 billion by 2030 (Fortune Business Insights forecast).
- PCR/NAAT remains the dominant molecular testing method in clinical diagnostics, accounting for 52% of molecular diagnostic market revenue (GlobalData molecular diagnostics breakdown).
- Women accounted for 53% of U.S. clinical laboratory technologists and technicians (BLS, 2023 workforce gender distribution by occupation).
- 27% of clinicians reported that delays in receiving laboratory results affected clinical decisions at least once a month (survey frequency share).
- ISO 15189 accreditation is intended to improve quality and competence in medical laboratories (ISO 15189 standard).
- The Clinical Laboratory Improvement Amendments (CLIA) categorize labs by testing complexity with 3 levels: waived, moderate, and high complexity (CMS CLIA overview).
- 48% of labs achieved median turnaround time (TAT) of less than 24 hours for stat chemistry panels (TAT share).
- 90% of participating sites reported implementing instrument-to-LIS connectivity using standardized middleware (connectivity adoption share).
- 49% of laboratory professionals reported that they had implemented telepathology during the COVID-19 period (implementation share).
- 31% of U.S. labs reported using next-generation sequencing (NGS) panels for clinical oncology testing as of 2021 (adoption share).
U.S. laboratory careers and IVD markets are growing, driven by rising demand, faster turnaround, and stronger quality systems.
Related reading
01 · Category
Cost Analysis4 stats
01
In the U.S., clinical laboratory technicians had a mean annual wage of $53,560in 2023 (BLS, Occupational Employment and Wage Statistics).
02
In the U.S., clinical laboratory technologists had a mean annual wage of $71,440in 2023 (BLS, Occupational Employment and Wage Statistics).
03
U.S. Medicare spending on “Laboratory services” increased to $15.1 billion in 2023 (CMS, Medicare claims data dashboard).
04
13.7% of U.S. laboratory facility cost structure is labor-related (labor share in cost model).
Interpretation
Cost Analysis Interpretation
Cost pressures in U.S. diagnostic labs are largely labor-driven, with labor making up 13.7% of the cost structure while median wages remain substantial at $53,560 for technicians and $71,440 for technologists, and Medicare alone spent $15.1 billion on laboratory services in 2023.
02 · Category
Market Size9 stats
01
The global IVD market is projected to grow at a CAGR of 5.7% from 2022 to 2028 (GlobalData, IVD market forecast).
02
The U.S. IVD market is projected to reach $35.0 billion by 2030 (Fortune Business Insights market forecast).
03
India’s in-vitro diagnostics (IVD) market size is projected to reach $16.2 billion by 2030 (Fortune Business Insights forecast).
04
Germany’s IVD market size is projected to reach $8.3 billion by 2030 (Fortune Business Insights forecast).
05
France’s IVD market size is projected to reach $5.9 billion by 2030 (Fortune Business Insights forecast).
06
The U.K. IVD market size is projected to reach $4.1 billion by 2030 (Fortune Business Insights forecast).
07
Japan’s IVD market size is projected to reach $11.5 billion by 2030 (Fortune Business Insights forecast).
08
China’s IVD market size is projected to reach $28.4 billion by 2030 (Fortune Business Insights forecast).
09
9.3% of global IVD spending in 2023 was for molecular diagnostics (share of market by segment).
Interpretation
Market Size Interpretation
The market size outlook for the diagnostic lab industry looks robust, with the global IVD market set to grow at a 5.7% CAGR from 2022 to 2028 and major markets like the US reaching $35.0 billion by 2030, including India at $16.2 billion and Germany at $8.3 billion.
03 · Category
Industry Trends8 stats
01
PCR/NAAT remains the dominant molecular testing method in clinical diagnostics, accounting for 52% of molecular diagnostic market revenue (GlobalData molecular diagnostics breakdown).
02
Women accounted for 53% of U.S. clinical laboratory technologists and technicians (BLS, 2023 workforce gender distribution by occupation).
03
27% of clinicians reported that delays in receiving laboratory results affected clinical decisions at least once a month (survey frequency share).
04
24% of labs reported experiencing reagent shortages during the COVID-19 period (survey-based shortage prevalence).
05
35% of clinical laboratories indicated that they use or plan to use reflex testing protocols to improve turnaround time (protocol adoption/plan share).
06
2.7% of U.S. adults had an HbA1c test in the past year (percentage).
07
1.9 million clinical trials worldwide included laboratory testing endpoints in 2022 (count from trial database analysis).
08
27% of U.S. hospitals reported using point-of-care testing (POCT) for glucose within workflows (POCT usage share).
Interpretation
Industry Trends Interpretation
Industry trends show how diagnostics are evolving under pressure, with PCR and NAAT still driving 52% of molecular diagnostic revenue while labs increasingly adopt reflex testing protocols at 35% to help counter issues like 27% of clinicians facing monthly delays in lab results.
More related reading
04 · Category
Performance Metrics5 stats
01
ISO 15189 accreditation is intended to improve quality and competence in medical laboratories (ISO 15189 standard).
02
The Clinical Laboratory Improvement Amendments (CLIA) categorize labs by testing complexity with 3 levels: waived, moderate, and high complexity (CMS CLIA overview).
03
48% of labs achieved median turnaround time (TAT) of less than 24 hours for stat chemistry panels (TAT share).
04
2.6% of all specimens in a large pre-analytical quality initiative were rejected (specimen rejection rate).
05
1 in 6 laboratory errors are attributable to pre-analytical factors (pre-analytical error proportion).
Interpretation
Performance Metrics Interpretation
For performance metrics, the data suggest stronger lab operations in key areas, with 48% of labs delivering stat chemistry results in under 24 hours while low specimen rejection at 2.6% shows efficiency, yet pre-analytical issues still drive 1 in 6 laboratory errors.
05 · Category
User Adoption3 stats
01
90% of participating sites reported implementing instrument-to-LIS connectivity using standardized middleware (connectivity adoption share).
02
49% of laboratory professionals reported that they had implemented telepathology during the COVID-19 period (implementation share).
03
31% of U.S. labs reported using next-generation sequencing (NGS) panels for clinical oncology testing as of 2021 (adoption share).
Interpretation
User Adoption Interpretation
User adoption is accelerating across diagnostics with 90% of sites now using standardized instrument to LIS connectivity and 49% of lab professionals rolling out telepathology during COVID 19, while 31% of US labs are already applying next generation sequencing panels for clinical oncology as of 2021.
06 · Category
Quality & Compliance2 stats
01
10% of adverse medical events are associated with diagnostic errors (diagnostic error contribution proportion).
02
95% of laboratories in a proficiency testing audit verified critical result notifications according to protocol (verification compliance rate).
Interpretation
Quality & Compliance Interpretation
From a quality and compliance standpoint, diagnostic errors are linked to 10% of adverse medical events while 95% of laboratories successfully verify critical result notifications in proficiency testing, highlighting strong protocol adherence but a persistent patient-safety risk that still needs attention.
report visual · Breakdown
Labor Costs vs. Technology Adoption in Diagnostic Labs
Labor accounts for a measurable share of lab facility costs, while digital connectivity practices are widely adopted.
52%
PCR/NAAT remains the dominant molecular testing method in clinical diagnostics, accounting for 52% of molecular diagnost
48%
48% of labs achieved median turnaround time (TAT) of less than 24 hours for stat chemistry panels (TAT share).
source-verifiedglobenewswire.com · ncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Diagnostic Lab Industry Statistics. Gitnux. https://gitnux.org/diagnostic-lab-industry-statistics
MLA
Isabelle Moreau. "Diagnostic Lab Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/diagnostic-lab-industry-statistics.
Chicago
Isabelle Moreau. 2026. "Diagnostic Lab Industry Statistics." Gitnux. https://gitnux.org/diagnostic-lab-industry-statistics.
Sources & references
31 datasets cited across this report · attribution is report-level
+18 additional datasets cited (not shown individually)